Why is Sandu Pharmaceuticals Ltd falling/rising?

Recent Price Movement and Market Context

Sandu Pharmaceuticals’ share price has been under pressure, having declined for two consecutive sessions, accumulating a loss of 5.49% over this period. The stock’s intraday low touched ₹37.81, marking a 5.78% drop from previous levels, signalling persistent selling interest. Despite this, the stock remains just 3.42% above its 52-week low of ₹36.76, indicating it is trading near its lowest levels in the past year.

When compared to the broader market, Sandu Pharmaceuticals has underperformed significantly on the day, lagging its sector by nearly 6%. This underperformance is particularly stark against the Sensex, which has shown modest gains over the past week and year-to-date, while Sandu’s returns have been mixed. For instance, over the past week, the stock gained 0.95% whereas the Sensex declined by 1.83%. However, over the one-month period, Sandu’s shares fell 3.65%, underperforming the Sensex’s 1.63% decline. More concerning is the stock’s long-term performance, with a 30.17% loss over the past year and a 40.53% decline over three years, contrasting sharply with the Sensex’s robust gains of 8.40% and 39.89% respectively during the same periods.

Technical Indicators and Trading Activity

Technical analysis reveals that Sandu Pharmaceuticals is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based weakness across multiple timeframes suggests a bearish trend and limited short-term support. The weighted average price for the day was closer to the low price, indicating that most trading volume occurred near the lower end of the price range, reinforcing selling pressure.

Investor participation appears to be waning, as evidenced by a sharp 78.19% decline in delivery volume on 9 Jan compared to the five-day average. This drop in delivery volume suggests reduced conviction among buyers, which often precedes further price weakness. Despite this, the stock maintains adequate liquidity, with trading volumes sufficient to support reasonable trade sizes, although the lack of strong buying interest remains a concern.

Long-Term Performance and Investor Sentiment

Sandu Pharmaceuticals’ long-term returns have been disappointing relative to the broader market. While the Sensex has delivered compounded gains of nearly 70% over five years, Sandu’s shares have only managed a modest 4.42% increase in the same period. This underperformance may reflect challenges specific to the company or sector, although no explicit positive or negative news has been reported recently to explain the stock’s current weakness.

Given the absence of positive catalysts and the prevailing technical downtrend, investor sentiment appears cautious. The stock’s proximity to its 52-week low and consistent underperformance against benchmarks may be prompting investors to reduce exposure or await clearer signs of recovery before committing fresh capital.

Conclusion

In summary, Sandu Pharmaceuticals Ltd’s recent share price decline on 12-Jan is primarily driven by technical weakness, reduced investor participation, and underperformance relative to market benchmarks. The stock’s trading below all major moving averages and near its 52-week low signals a bearish trend, while falling delivery volumes indicate diminished buying interest. Without fresh positive developments or a reversal in technical indicators, the stock may continue to face downward pressure in the near term. Investors should monitor volume trends and moving averages closely to gauge any potential recovery or further deterioration in momentum.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →